Drug Combination Details
| General Information of the Combination (ID: C77125) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Canstatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PCNA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| In-vivo Model | To establish nude mouse transplantation tumor model, 0.2 ml of HepG2 cells (1 * 107/ml) were injected subcutaneously in the right axilla of mice. | |||||
| Experimental
Result(s) |
Combined canstatin and ATO significantly inhibited cell proliferation, migration and adhesion abilities, and promoted cell apoptosis, and inhibited tumor growth, thus suppressed the progression of HCC. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination of canstatin and arsenic trioxide suppresses the development of hepatocellular carcinoma. Drug Dev Res. 2021 May;82(3):430-439. | |||
